Post-hoc analysis in ESMO Open  in 2021 pointed to an atezolizumab OS benefit among SAUL participants who had previously received cisplatin or carboplatin, and identified prognostic markers for OS with second-line atezolizumab, including Bellmunt risk and PD-L1 expression.

The study included data on 121 individuals who received PD-1 or PD-L1 inhibitors for metastatic UC at one of three Canadian cancer centers between 2016 and 2021.

The team queried the Mass General-Brigham/Dana-Farber Cancer Institute registry and identified eight patients who received acitretin for multikinase inhibitor-induced HFSR between January 2000 and March 2021.

A literature search was conducted of MEDLINE® ALL and EMBASE databases for published studies (2000–August 2021) using keywords related to ‘fibromatosis aggressive’, ‘immunohistochemistry’, ‘polymerase chain reaction’ and ‘mutation’.

The document follows the ESMO standard operating procedures  for Clinical Practice Guideline development and is published in the Annals of Oncology . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Ann Oncol 2021; doi:10.1016/j.annonc.2022.01.002

Enfortumab vedotin is associated with better advanced urothelial cancer outcomes than standard chemotherapy even in patients with poor prognostic factors, suggests a subgroup analysis of the EV-301 study presented at the ESMO Congress 2021.

medwireNews : A Clinical Practice Guideline for the management of bladder cancer has been developed by ESMO and published in the Annals of Oncology .

medwireNews : ESMO has released a Clinical Practice Guideline to assist physicians in managing people with malignant pleural mesothelioma.

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

Multigene sequencing identifies patients with metastatic breast cancer who will benefit from targeted therapy, but its use must be driven by a framework of actionability, show data presented at the 2021 San Antonio Breast Cancer Symposium.

Almost three times as many patients given chemoimmunotherapy were alive at 3 years as those given chemotherapy alone, investigator Luis Paz-Ares (Hospital Universitario 12 de Octubre, Madrid, Spain) told the audience at the ESMO Congress 2021.

ESMO Congress 2021; 16–21 September

Giuseppe Curigliano, Chair of the ESMO Guidelines Committee, noted in a press release that the document is “designed to integrate even the most recent, potentially practice-changing data by providing graded recommendations for different treatment choices according to the levels of evidence available to support them, based on their rating within the ESMO Magnitude of Clinical Benefit Scale and the ESMO Scale for the Clinical Actionability of Molecular Targets.”

Reporting the findings in a poster at the ESMO Congress 2021, Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, USA) and co-investigators highlighted the “durable responses and long-term survival” observed with the PD-L1 inhibitor in this patient population.

Cristina Saura Manich (Hospital Universitari Vall d’Hebron, Barcelona, Spain) presented results of the phase 3 trial at the ESMO Congress 2021, reporting on 437 patients who had received prior trastuzumab emtansine (T-DM1) or at least two other treatments for metastatic disease.

Presenting the findings at the ESMO Congress 2021, Shahneen Sandhu, from Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia, said that the radiolabeled small molecule has demonstrated beneficial outcomes in both the TheraP and VISION studies of patients with mCRPC.

Hortobagyi added: “The MONALEESA trials with ribociclib demonstrate a consistent overall survival benefit regardless of endocrine therapy partner, line of therapy, or menopausal status.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2021; 16–21 September

ESMO Congress 2021; 16–21 September

And this observation may also explain results of previous studies with shorter follow-up, including the SALSA trial , that found no benefit with extended letrozole. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2021; 16–21 September Lancet Oncol 2021; doi:10.1016/S1470-2045(21)00352-1